

- macol.* 1983, 32, 2929.
- Argiolas, A.; Pisano, J. J. *J. Biol. Chem.* 1983, 258, 13697.
  - Higashijima, S.; Uzu, S.; Nakajima, T.; Ross, E. M. *J. Biol. Commun.* 1988, 263, 6491.
  - Okmura, K.; Inui, K.; Hirai, Y.; Nakajima, T. *Biomed. Res.* 1981, 2, 450.
  - Park, N. G.; Yamato, Y.; Lee, S.; Sugihara, G.; Park, J.-S.; Kang, S.-W. *Bull. Korean Chem. Soc.* 1996, 17, 239.

- Gad, A. E.; Silver, B. L.; Eytan, G. D. *Biochim. Biophys. Acta.* 1982, 690, 124.
- Surewics, R. M.; Eppard, R. M.; Vail, W. J.; Moscarelo, M. A. *Biochim. Biophys. Acta.* 1985, 820, 310.
- Uster, P. S.; Deamer, D. W. *Biochemistry* 1985, 24, 1.
- Wang, C.-Y.; Huang, L. *Biochemistry* 1984, 23, 4409.
- Terbeest, M. B. A.; Hoekstra, D. *Eur. J. Biochem.* 1993, 221, 689.


## Versatile Synthetic Routes to Enantiomeric Dihydroxyethylene Dipeptide Isosteres via Intramolecular Amidation

Sung Ho Kang\* and Hyeong-wook Choi

Department of Chemistry, Korea Advanced Institute of Science and Technology, Taejon 305-701, Korea

Received November 15, 1996


Since the aspartic protease renin catalyzes the hydrolysis of angiotensinogen to angiotensin I,<sup>1</sup> its inhibitors are expected to be of potential use in the treatment of hypertension and congestive heart failure.<sup>1,2</sup> Based on the transition state mimic of the scissile Leu-Val amide bond in angiotensinogen, the dihydroxyethylene dipeptide (DHED) isostere **1** was designed as a prospective C-terminal component for the development of renin inhibitors.<sup>3</sup> Several synthetic approaches to **1** have been described by employing stereoselective alkylation of imines,<sup>4</sup> one-pot reductive amination of epoxy ketone,<sup>5</sup> ring-opening of epoxides with sodium azide,<sup>6</sup> diastereoselective dihydroxylation of allylic amines<sup>7</sup> and enzymatic resolution.<sup>8</sup> Recently we have rein-




vestigated the electrophile promoted cyclization of trichloroacetimidates from allylic and homoallylic alcohols to attain a highly stereoselective amidation.<sup>9</sup> In this paper we report a divergent synthetic route to **1** and its enantiomer *ent*-**1** by extending the cyclization protocol to the stereocontrolled intramolecular amidation of trichloroacetimidates from (3*R*,4*S*)-3,4-dihydroxy-6-methyl-1-heptene **4** and (2*R*,3*S*)-1,2,3-trihydroxy-5-pentene **9**.

The synthesis of DHED isostere **1** was initiated with DIBAL reduction of the known lactone **2**<sup>10</sup> followed by Wittig isopropylation and hydrogenation to give alcohol **3** in 87% overall yield (Scheme 1). Swern oxidation<sup>11</sup> of **3** and the subsequent methylenation provided the volatile methylenic acetonide in 69% yield. Its acidic hydrolysis afforded (3*R*,4*S*)-3,4-dihydroxy-6-methyl-1-heptene **4**, mp 55-56 °C,

$[\alpha]_D^{15} - 13.5$  (CHCl<sub>3</sub>, *c* 1.00) in 88% yield, of which the physical constants were appreciably higher than the reported values.<sup>4,12</sup> For the intended functionalization of the olefinic double bond in **4**, it reacted with trichloroacetonitrile and DBU, and the generated bis(trichloroacetimidate) was cyclized using iodine in the presence of sodium bicarbonate in acetonitrile at 0 °C to furnish a 3.7 : 1 mixture of dihydro-1,3-oxazines **5** and oxazolines **6** in 89% combined yield. While the isomeric ratio of **5** turned out to be 28 : 1 in favor of **5s**, mp 93-95 °C,  $[\alpha]_D^{10} + 22.5$  (CHCl<sub>3</sub>, *c* 1.10), only *trans* isomer **6s**, mp 81-82 °C,  $[\alpha]_D^{18} - 87.4$  (CHCl<sub>3</sub>, *c* 1.04) was found in the case of **6**. The structures of **5s** and **6s** were corroborated from the following C=N stretching band frequencies<sup>13</sup> and proton-proton coupling constants: for **5s**: 1672 cm<sup>-1</sup>,  $J_{H_4,H_5} = 3.1$  Hz and  $J_{H_5,H_6} = 0$  Hz. For **6s**: 1666 cm<sup>-1</sup> and  $J_{H_4,H_5} = 5.9$  Hz. The assignments were supported by the derivatization of **5s** and **6s** into the identical Boc-aziridine **7** (*vide infra*).



**Scheme 1.** <sup>a</sup> DIBAL/CH<sub>2</sub>Cl<sub>2</sub>/-78 °C. <sup>b</sup> Me<sub>2</sub>CH<sup>+</sup>PPh<sub>3</sub>I/*n*-BuLi/HMPA/THF/0 °C → rt. <sup>c</sup> H<sub>2</sub>/10% Pd-C/NaHCO<sub>3</sub>/MeOH/rt. <sup>d</sup> Swern ox. <sup>e</sup> Me<sup>+</sup>PPh<sub>3</sub>I/*n*-BuLi/HMPA/THF/0 °C. <sup>f</sup> AcOH/H<sub>2</sub>O/45 °C. <sup>g</sup> Cl<sub>3</sub>CCN/DBU/MeCN/0 °C. <sup>h</sup> I<sub>2</sub>/NaHCO<sub>3</sub>/MeCN/0 °C. <sup>i</sup> 6 N HCl/MeOH/rt. <sup>j</sup> NaHCO<sub>3</sub>/MeOH/rt; Boc<sub>2</sub>O/rt. <sup>k</sup> TMSOTf/HMDS/THF/-40 °C; *c*-HxMgCl/Li<sub>2</sub>CuCl<sub>4</sub>/-30 °C; acidic work-up (pH=2-3).



**Scheme 2.** <sup>a</sup> DIBAL/CH<sub>2</sub>Cl<sub>2</sub>/-78 °C. <sup>b</sup> Me<sup>+</sup>PPh<sub>3</sub>I/*n*-BuLi/HMPA/THF/0 °C → rt. <sup>c</sup> AcOH/H<sub>2</sub>O/50 °C. <sup>d</sup> Cl<sub>3</sub>CCN/DBU/MeCN/-30 °C. <sup>e</sup> I<sub>2</sub>/NaHCO<sub>3</sub>/MeCN/0 °C → rt. <sup>f</sup> 6 N HCl/MeOH/rt. <sup>g</sup> Boc<sub>2</sub>O/NaHCO<sub>3</sub>/MeOH/0 °C. <sup>h</sup> TsCl/DMAP/Et<sub>3</sub>N/CH<sub>2</sub>Cl<sub>2</sub>/0 °C. <sup>i</sup> TMSOTf/HMDS/THF/0 °C; LDA/-20 °C; <sup>j</sup> *c*-HxMgCl/Li<sub>2</sub>CuCl<sub>4</sub>/-30 °C. <sup>k</sup> K<sub>2</sub>CO<sub>3</sub>/MeOH/0 °C. <sup>l</sup> Me<sub>2</sub>CHMgCl/Li<sub>2</sub>CuCl<sub>4</sub>/THF/-20 °C.

After chromatographic removal of **5a**, the mixture of **5s** and **6s** was completely deprotected with methanolic HCl, and the resulting amino iodide was sequentially treated with sodium bicarbonate and di-*t*-butyl dicarbonate to produce Boc-aziridine **7**,  $[\alpha]_D^{25} -39.5$  (CHCl<sub>3</sub>, *c* 1.16) in 77% overall yield. Since it was necessary to protect the hydroxy groups in **7** for the regioselective opening of its aziridine ring, they were silylated with hexamethyldisilazane (HMDS) and trimethylsilyl triflate (TMSOTf).<sup>14</sup> The protected aziridine was subjected to cyclohexylmagnesium chloride in the presence of dilithium tetrachlorocuprate and the ensuing acidic work-up provided the desired Boc-protected DHED isostere **8**<sup>a</sup>, mp 128.5-130 °C,  $[\alpha]_D^{25} -64.8$  (CHCl<sub>3</sub>, *c* 1.00) in 81% overall yield.<sup>15</sup>

For the preparation of the enantiomeric DHED isostere *ent*-**1**, lactone **2** was reduced with DIBAL, methylenated and then hydrolyzed in aqueous acetic acid to afford trihydroxypentene **9**,  $[\alpha]_D^{19} -28.4$  (MeOH, *c* 1.01) in 77% overall yield (Scheme 2). After converting **9** into tris(trichloroacetimidate), its olefinic double bond was intramolecularly iodoaminated with iodine to furnish a 2-3:1 mixture of oxazolines **10** and dihydro-1,3-oxazines **11**. The major isomers **10** and **11** were determined to be **10s**,  $[\alpha]_D^{17} +56.5$  (CHCl<sub>3</sub>, *c* 1.00) and **11s**,  $[\alpha]_D^{17} +6.8$  (CHCl<sub>3</sub>, *c* 1.07), respectively, based on the C=N stretching band frequencies and proton-proton coupling constants as follows: for **10s**: 1669 cm<sup>-1</sup> and  $J_{H_4, H_5} = 5.5$  Hz. For **11s**: 1673 cm<sup>-1</sup>,  $J_{H_4, H_5} = 3.3$  Hz and  $J_{H_5, H_6} = 1.6$  Hz.

Since its separation was not facile, the mixture was completely hydrolyzed with methanolic HCl, and the unmasked amino and primary hydroxy groups were derivatized into *t*-butyl carbamate and tosylate, respectively, to produce a readily separable 38:1 mixture of iodide **12s**, mp 103.5-104 °C,  $[\alpha]_D^{19} +22.9$  (CHCl<sub>3</sub>, *c* 1.05) and **12a** in 70% combined yield. Although cyclohexylcuprate reaction of **12s** did not proceed, the substitution reaction could be accomplished with the corresponding Boc-aziridine, of which the hydroxy groups should be protected for the complete regioselectivity. Accordingly **12s** was silylated, cyclized with LDA and substituted with cyclohexylmagnesium chloride in the presence

of dilithium tetrachlorocuprate in one pot to give tosylate **13**,  $[\alpha]_D^{11} +24.3$  (CHCl<sub>3</sub>, *c* 0.97) in 71% overall yield. Desilylation and the following epoxide formation were effected in 89% yield by methanolic potassium carbonate at 0 °C. The resultant epoxide, mp 106.5-107.5 °C,  $[\alpha]_D^{18} +72.3$  (CHCl<sub>3</sub>, *c* 1.02) was exposed to isopropylmagnesium chloride in the presence of dilithium tetrachlorocuprate to provide another desired Boc-protected DHED isostere **14**<sup>16</sup>, mp 128.5-130 °C,  $[\alpha]_D^{19} +67.8$  (CHCl<sub>3</sub>, *c* 1.01) in 74% yield along with 8% of ketone **15** and 3% of alkene **16**.

In summary we have established enantioselective synthetic routes to DHED isosteres **1** and *ent*-**1** via the intramolecular amidation of olefinic trichloroacetimidates, of which the stereoselectivity was higher than 94% ee.

**Acknowledgment.** This work was supported by the Korea Advanced Institute of Science and Technology, and the Organic Chemistry Research Center sponsored by the Korea Science and Engineering Foundation.

## References

- Boger, J. *Annual Reports in Medicinal Chemistry*; Bailey, D. M.; Egan, R. W. Eds.; Academic Press: New York, 1985; Vol. 20, p 257.
- (a) Greenlee, W. J. *Pharm. Res.* **1987**, *4*, 364-374. (b) Greenlee, W. J. *Med. Res. Rev.* **1990**, *10*, 173-236.
- (a) Luly, J. R.; BaMaung, N.; Soderquist, J.; Fung, A. K. L.; Stein, H.; Kleinert, H. D.; Marcotte, P. A.; Egan, D. A.; Bopp, B.; Meritis, I.; Bolis, G.; Greer, J.; Perun, T. J.; Plattner, J. J. *J. Med. Chem.* **1988**, *31*, 2264-2276. (b) Kleinert, H. D.; Rosenberg, S. H.; Baker, W. R.; Stein, H. H.; Klinghofer, V.; Barlow, J.; Spina, K.; Polakowski, J.; Kovar, P.; Cohen, J.; Denissen, J. *Science* **1992**, *257*, 1940-1944.
- Baker, W. R.; Condon, S. L. *J. Org. Chem.* **1993**, *58*, 3277-3284.
- Wood, J. L.; Jones, D. R.; Hirschmann, R.; Smith, A. B., III *Tetrahedron Lett.* **1990**, *31*, 6329-6330.
- Chan, M. F.; Hsiao, C.-N. *Tetrahedron Lett.* **1992**, *33*, 3567-3570.
- (a) Luly, J. R.; Hsiao, C.-N.; BaMaung, N.; Plattner, J. J. *J. Org. Chem.* **1988**, *53*, 6109-6112. (b) Krysan, D. J.; Rockway, T. W.; Haight, A. R. *Tetrahedron: Asymmetry* **1994**, *5*, 625-632.
- Spero, D. M.; Kapadia, S.; Farina, V. *Tetrahedron Lett.* **1995**, *36*, 4543-4546.
- Kang, S. H.; Ryu, D. H. *Bioorg. Med. Chem. Lett.* **1995**, *5*, 2959-2962.
- Cohen, N.; Banner, B. L.; Laurenzano, A. J.; Carrozza, L. *Organic Syntheses*; 1990; Coll. Vol. 7, 297-301.
- Mancuso, A. J.; Swern, D. *Synthesis* **1981**, 165-185.
- The reported mp. and  $[\alpha]_D^{25}$ : 42-46 °C and -9.8 (CHCl<sub>3</sub>, *c* 1.0).<sup>4</sup>
- Bongini, A.; Cardillo, G.; Orena, M.; Sandri, S.; Tomasini, C. *J. Org. Chem.* **1986**, *51*, 4905-4910.
- Harada, T.; Kurokawa, H.; Oku, A. *Tetrahedron Lett.* **1987**, *28*, 4843-4846.
- Cyclohexylcuprate reaction of the unprotected aziridine **7** yielded 72% of **8** along with 8-10% of the corresponding regioisomer.
- All new compounds showed satisfactory spectral data.